Newsletter
16 de April de 2025
Medicinal Cannabis Review: Public Consultation 1.316/2025 open
The Public Consultation (CP) No. 1.316/2025, which aims to initiate the review process of Collegiate Board Resolution (RDC) No. 327/2019 from the National Health Surveillance Agency (Anvisa), remains open until June 3, 2025. This resolution establishes the procedures for granting Sanitary Authorization for the manufacture and import of Cannabis products for medicinal purposes, in addition to defining the requirements for their commercialization, prescription, dispensation, monitoring, and inspection.
RDC No. 327/2019 defined, on a transitory basis, the regulatory category of Cannabis products, encompassing industrialized products for human medicinal use that contain active ingredients obtained from the Cannabis sativa plant species. Article 77 of this Resolution stipulated a period of three years, following its publication, for the revision of the normative text.
In this context, Anvisa conducted a Regulatory Impact Analysis (AIR), identifying the need for adjustments to improve the clarity and effectiveness of the regulations. As a result, it was decided to maintain the transitional category for these products, while implementing new requirements to ensure transparency throughout the process, as well as the safety and quality of the products.
Thus, the main objective of the CP is to update and improve the regulations related to prescription, good manufacturing practices, dispensing, monitoring, advertising, inspection, and labeling of Cannabis products for medicinal purposes. This initiative aims to ensure a significant increase in the safety and quality of these products.
The Public Consultation will be available for contributions from April 4th to June 3rd, 2025. During this period, all interested parties may submit their suggestions and comments regarding the presented proposals. Public participation is considered essential for the improvement of the regulation, ensuring that the new rules adequately meet the needs of the sector.
For more content related to Anvisa and other developments regarding Public Consultation No. 1.316/2025, do not hesitate to contact us at the email: regulatorio@kasznarleonardos.com.
Last related news
24 de July de 2025
Countdown: 30 days to comply with Brazilian Rules about International Data Transfer
On August 23, 2024, the Brazilian Data Protection Authority (“ANPD”) published the Resolution CD/ANPD No. 19/2024, which approved the regulation on international … Countdown: 30 days to comply with Brazilian Rules about International Data Transfer
22 de July de 2025
Intellectual property in the workplace: real risks for companies and employees
Respect for intellectual property rights, especially regarding the use of licensed software, is a critical obligation in today’s corporate environment. Installing or … Intellectual property in the workplace: real risks for companies and employees
9 de July de 2025
Tracking and Telemetry in the Fight Against Software Piracy: An Analysis Under the LGPD and GDPR
The use of telemetry and tracking technologies by software developers to detect and combat the unauthorized use of their products has become … Tracking and Telemetry in the Fight Against Software Piracy: An Analysis Under the LGPD and GDPR